Pub Date : 2024-09-10DOI: 10.1016/j.ajhg.2024.08.011
Hadley Stevens Smith,Bethany Zettler,Casie A Genetti,Madison R Hickingbotham,Tanner F Coleman,Matthew Lebo,Anna Nagy,Hana Zouk,Lisa Mahanta,Kurt D Christensen,Stacey Pereira,Nidhi D Shah,Nina B Gold,Sheyenne Walmsley,Sarita Edwards,Ramin Homayouni,Graham P Krasan,Hakon Hakonarson,Carol R Horowitz,Bruce D Gelb,Bruce R Korf,Amy L McGuire,Ingrid A Holm,Robert C Green
Efforts to implement and evaluate genome sequencing (GS) as a screening tool for newborns and infants are expanding worldwide. The first iteration of the BabySeq Project (2015-2019), a randomized controlled trial of newborn sequencing, produced novel evidence on medical, behavioral, and economic outcomes. The second iteration of BabySeq, which began participant recruitment in January 2023, examines GS outcomes in a larger, more diverse cohort of more than 500 infants up to one year of age recruited from pediatric clinics at several sites across the United States. The trial aims for families who self-identify as Black/African American or Hispanic/Latino to make up more than 50% of final enrollment, and key aspects of the trial design were co-developed with a community advisory board. All enrolled families receive genetic counseling and a family history report. Half of enrolled infants are randomized to receive GS with comprehensive interpretation of pathogenic and likely pathogenic variants in more than 4,300 genes associated with childhood-onset and actionable adult-onset conditions, as well as larger-scale chromosomal copy number variants classified as pathogenic or likely pathogenic. GS result reports include variants associated with disease (Mendelian disease risks) and carrier status of autosomal-recessive and X-linked disorders. Investigators evaluate the utility and impacts of implementing a GS screening program in a diverse cohort of infants using medical record review and longitudinal parent surveys. In this perspective, we describe the rationale for the second iteration of the BabySeq Project, the outcomes being assessed, and the key decisions collaboratively made by the study team and community advisory board.
{"title":"The BabySeq Project: A clinical trial of genome sequencing in a diverse cohort of infants.","authors":"Hadley Stevens Smith,Bethany Zettler,Casie A Genetti,Madison R Hickingbotham,Tanner F Coleman,Matthew Lebo,Anna Nagy,Hana Zouk,Lisa Mahanta,Kurt D Christensen,Stacey Pereira,Nidhi D Shah,Nina B Gold,Sheyenne Walmsley,Sarita Edwards,Ramin Homayouni,Graham P Krasan,Hakon Hakonarson,Carol R Horowitz,Bruce D Gelb,Bruce R Korf,Amy L McGuire,Ingrid A Holm,Robert C Green","doi":"10.1016/j.ajhg.2024.08.011","DOIUrl":"https://doi.org/10.1016/j.ajhg.2024.08.011","url":null,"abstract":"Efforts to implement and evaluate genome sequencing (GS) as a screening tool for newborns and infants are expanding worldwide. The first iteration of the BabySeq Project (2015-2019), a randomized controlled trial of newborn sequencing, produced novel evidence on medical, behavioral, and economic outcomes. The second iteration of BabySeq, which began participant recruitment in January 2023, examines GS outcomes in a larger, more diverse cohort of more than 500 infants up to one year of age recruited from pediatric clinics at several sites across the United States. The trial aims for families who self-identify as Black/African American or Hispanic/Latino to make up more than 50% of final enrollment, and key aspects of the trial design were co-developed with a community advisory board. All enrolled families receive genetic counseling and a family history report. Half of enrolled infants are randomized to receive GS with comprehensive interpretation of pathogenic and likely pathogenic variants in more than 4,300 genes associated with childhood-onset and actionable adult-onset conditions, as well as larger-scale chromosomal copy number variants classified as pathogenic or likely pathogenic. GS result reports include variants associated with disease (Mendelian disease risks) and carrier status of autosomal-recessive and X-linked disorders. Investigators evaluate the utility and impacts of implementing a GS screening program in a diverse cohort of infants using medical record review and longitudinal parent surveys. In this perspective, we describe the rationale for the second iteration of the BabySeq Project, the outcomes being assessed, and the key decisions collaboratively made by the study team and community advisory board.","PeriodicalId":7659,"journal":{"name":"American journal of human genetics","volume":"17 1","pages":""},"PeriodicalIF":9.8,"publicationDate":"2024-09-10","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"142259773","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":1,"RegionCategory":"生物学","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}
Pub Date : 2024-09-05DOI: 10.1016/j.ajhg.2024.08.006
Alyson B. Barnes, Kylee L. Spencer
{"title":"This Month in The Journal","authors":"Alyson B. Barnes, Kylee L. Spencer","doi":"10.1016/j.ajhg.2024.08.006","DOIUrl":"https://doi.org/10.1016/j.ajhg.2024.08.006","url":null,"abstract":"","PeriodicalId":7659,"journal":{"name":"American journal of human genetics","volume":"4 1","pages":""},"PeriodicalIF":9.8,"publicationDate":"2024-09-05","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"142231775","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":1,"RegionCategory":"生物学","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}
Pub Date : 2024-09-05Epub Date: 2024-08-12DOI: 10.1016/j.ajhg.2024.07.012
Diptavo Dutta, Xinyu Guo, Timothy D Winter, Om Jahagirdar, Eunji Ha, Katalin Susztak, Mitchell J Machiela, Stephen J Chanock, Mark P Purdue
We performed a series of integrative analyses including transcriptome-wide association studies (TWASs) and proteome-wide association studies (PWASs) of renal cell carcinoma (RCC) to nominate and prioritize molecular targets for laboratory investigation. On the basis of a genome-wide association study (GWAS) of 29,020 affected individuals and 835,670 control individuals and prediction models trained in transcriptomic reference models, our TWAS across four kidney transcriptomes (GTEx kidney cortex, kidney tubules, TCGA-KIRC [The Cancer Genome Atlas kidney renal clear-cell carcinoma], and TCGA-KIRP [TCGA kidney renal papillary cell carcinoma]) identified 38 gene associations (false-discovery rate <5%) in at least two of four transcriptomic panels and identified 12 genes that were independent of GWAS susceptibility regions. Analyses combining TWAS associations across 48 tissues from GTEx identified associations that were replicable in tumor transcriptomes for 23 additional genes. Analyses by the two major histologic types (clear-cell RCC and papillary RCC) revealed subtype-specific associations, although at least three gene associations were common to both subtypes. PWAS identified 13 associated proteins, all mapping to GWAS-significant loci. TWAS-identified genes were enriched for active enhancer or promoter regions in RCC tumors and hypoxia-inducible factor binding sites in relevant cell lines. Using gene expression correlation, common cancers (breast and prostate) and RCC risk factors (e.g., hypertension and BMI) display genetic contributions shared with RCC. Our work identifies potential molecular targets for RCC susceptibility for downstream functional investigation.
{"title":"Transcriptome- and proteome-wide association studies identify genes associated with renal cell carcinoma.","authors":"Diptavo Dutta, Xinyu Guo, Timothy D Winter, Om Jahagirdar, Eunji Ha, Katalin Susztak, Mitchell J Machiela, Stephen J Chanock, Mark P Purdue","doi":"10.1016/j.ajhg.2024.07.012","DOIUrl":"10.1016/j.ajhg.2024.07.012","url":null,"abstract":"<p><p>We performed a series of integrative analyses including transcriptome-wide association studies (TWASs) and proteome-wide association studies (PWASs) of renal cell carcinoma (RCC) to nominate and prioritize molecular targets for laboratory investigation. On the basis of a genome-wide association study (GWAS) of 29,020 affected individuals and 835,670 control individuals and prediction models trained in transcriptomic reference models, our TWAS across four kidney transcriptomes (GTEx kidney cortex, kidney tubules, TCGA-KIRC [The Cancer Genome Atlas kidney renal clear-cell carcinoma], and TCGA-KIRP [TCGA kidney renal papillary cell carcinoma]) identified 38 gene associations (false-discovery rate <5%) in at least two of four transcriptomic panels and identified 12 genes that were independent of GWAS susceptibility regions. Analyses combining TWAS associations across 48 tissues from GTEx identified associations that were replicable in tumor transcriptomes for 23 additional genes. Analyses by the two major histologic types (clear-cell RCC and papillary RCC) revealed subtype-specific associations, although at least three gene associations were common to both subtypes. PWAS identified 13 associated proteins, all mapping to GWAS-significant loci. TWAS-identified genes were enriched for active enhancer or promoter regions in RCC tumors and hypoxia-inducible factor binding sites in relevant cell lines. Using gene expression correlation, common cancers (breast and prostate) and RCC risk factors (e.g., hypertension and BMI) display genetic contributions shared with RCC. Our work identifies potential molecular targets for RCC susceptibility for downstream functional investigation.</p>","PeriodicalId":7659,"journal":{"name":"American journal of human genetics","volume":" ","pages":"1864-1876"},"PeriodicalIF":8.1,"publicationDate":"2024-09-05","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"https://www.ncbi.nlm.nih.gov/pmc/articles/PMC11393681/pdf/","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"141974865","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":1,"RegionCategory":"生物学","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"OA","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}
Pub Date : 2024-09-05Epub Date: 2024-08-14DOI: 10.1016/j.ajhg.2024.07.011
Kendall A Flaharty, Ping Hu, Suzanna Ledgister Hanchard, Molly E Ripper, Dat Duong, Rebekah L Waikel, Benjamin D Solomon
Large language models (LLMs) are generating interest in medical settings. For example, LLMs can respond coherently to medical queries by providing plausible differential diagnoses based on clinical notes. However, there are many questions to explore, such as evaluating differences between open- and closed-source LLMs as well as LLM performance on queries from both medical and non-medical users. In this study, we assessed multiple LLMs, including Llama-2-chat, Vicuna, Medllama2, Bard/Gemini, Claude, ChatGPT3.5, and ChatGPT-4, as well as non-LLM approaches (Google search and Phenomizer) regarding their ability to identify genetic conditions from textbook-like clinician questions and their corresponding layperson translations related to 63 genetic conditions. For open-source LLMs, larger models were more accurate than smaller LLMs: 7b, 13b, and larger than 33b parameter models obtained accuracy ranges from 21%-49%, 41%-51%, and 54%-68%, respectively. Closed-source LLMs outperformed open-source LLMs, with ChatGPT-4 performing best (89%-90%). Three of 11 LLMs and Google search had significant performance gaps between clinician and layperson prompts. We also evaluated how in-context prompting and keyword removal affected open-source LLM performance. Models were provided with 2 types of in-context prompts: list-type prompts, which improved LLM performance, and definition-type prompts, which did not. We further analyzed removal of rare terms from descriptions, which decreased accuracy for 5 of 7 evaluated LLMs. Finally, we observed much lower performance with real individuals' descriptions; LLMs answered these questions with a maximum 21% accuracy.
{"title":"Evaluating large language models on medical, lay-language, and self-reported descriptions of genetic conditions.","authors":"Kendall A Flaharty, Ping Hu, Suzanna Ledgister Hanchard, Molly E Ripper, Dat Duong, Rebekah L Waikel, Benjamin D Solomon","doi":"10.1016/j.ajhg.2024.07.011","DOIUrl":"10.1016/j.ajhg.2024.07.011","url":null,"abstract":"<p><p>Large language models (LLMs) are generating interest in medical settings. For example, LLMs can respond coherently to medical queries by providing plausible differential diagnoses based on clinical notes. However, there are many questions to explore, such as evaluating differences between open- and closed-source LLMs as well as LLM performance on queries from both medical and non-medical users. In this study, we assessed multiple LLMs, including Llama-2-chat, Vicuna, Medllama2, Bard/Gemini, Claude, ChatGPT3.5, and ChatGPT-4, as well as non-LLM approaches (Google search and Phenomizer) regarding their ability to identify genetic conditions from textbook-like clinician questions and their corresponding layperson translations related to 63 genetic conditions. For open-source LLMs, larger models were more accurate than smaller LLMs: 7b, 13b, and larger than 33b parameter models obtained accuracy ranges from 21%-49%, 41%-51%, and 54%-68%, respectively. Closed-source LLMs outperformed open-source LLMs, with ChatGPT-4 performing best (89%-90%). Three of 11 LLMs and Google search had significant performance gaps between clinician and layperson prompts. We also evaluated how in-context prompting and keyword removal affected open-source LLM performance. Models were provided with 2 types of in-context prompts: list-type prompts, which improved LLM performance, and definition-type prompts, which did not. We further analyzed removal of rare terms from descriptions, which decreased accuracy for 5 of 7 evaluated LLMs. Finally, we observed much lower performance with real individuals' descriptions; LLMs answered these questions with a maximum 21% accuracy.</p>","PeriodicalId":7659,"journal":{"name":"American journal of human genetics","volume":" ","pages":"1819-1833"},"PeriodicalIF":8.1,"publicationDate":"2024-09-05","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"https://www.ncbi.nlm.nih.gov/pmc/articles/PMC11393706/pdf/","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"141987254","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":1,"RegionCategory":"生物学","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"OA","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}
Pub Date : 2024-09-05Epub Date: 2024-08-26DOI: 10.1016/j.ajhg.2024.07.020
Samantha Malka, Pooja Biswas, Anne-Marie Berry, Riccardo Sangermano, Mukhtar Ullah, Siying Lin, Matteo D'Antonio, Aleksandr Jestin, Xiaodong Jiao, Mathieu Quinodoz, Lori Sullivan, Jessica C Gardner, Emily M Place, Michel Michaelides, Karolina Kaminska, Omar A Mahroo, Elena Schiff, Genevieve Wright, Francesca Cancellieri, Veronika Vaclavik, Cristina Santos, Atta Ur Rehman, Sudeep Mehrotra, Hafiz Muhammad Azhar Baig, Muhammad Iqbal, Muhammad Ansar, Luisa Coutinho Santos, Ana Berta Sousa, Viet H Tran, Hiroko Matsui, Anjana Bhatia, Muhammad Asif Naeem, Shehla J Akram, Javed Akram, Sheikh Riazuddin, Carmen Ayuso, Eric A Pierce, Alison J Hardcastle, S Amer Riazuddin, Kelly A Frazer, J Fielding Hejtmancik, Carlo Rivolta, Kinga M Bujakowska, Gavin Arno, Andrew R Webster, Radha Ayyagari
Genome analysis of individuals affected by retinitis pigmentosa (RP) identified two rare nucleotide substitutions at the same genomic location on chromosome 11 (g.61392563 [GRCh38]), 69 base pairs upstream of the start codon of the ciliopathy gene TMEM216 (c.-69G>A, c.-69G>T [GenBank: NM_001173991.3]), in individuals of South Asian and African ancestry, respectively. Genotypes included 71 homozygotes and 3 mixed heterozygotes in trans with a predicted loss-of-function allele. Haplotype analysis showed single-nucleotide variants (SNVs) common across families, suggesting ancestral alleles within the two distinct ethnic populations. Clinical phenotype analysis of 62 available individuals from 49 families indicated a similar clinical presentation with night blindness in the first decade and progressive peripheral field loss thereafter. No evident systemic ciliopathy features were noted. Functional characterization of these variants by luciferase reporter gene assay showed reduced promotor activity. Nanopore sequencing confirmed the lower transcription of the TMEM216 c.-69G>T allele in blood-derived RNA from a heterozygous carrier, and reduced expression was further recapitulated by qPCR, using both leukocytes-derived RNA of c.-69G>T homozygotes and total RNA from genome-edited hTERT-RPE1 cells carrying homozygous TMEM216 c.-69G>A. In conclusion, these variants explain a significant proportion of unsolved cases, specifically in individuals of African ancestry, suggesting that reduced TMEM216 expression might lead to abnormal ciliogenesis and photoreceptor degeneration.
{"title":"Substitution of a single non-coding nucleotide upstream of TMEM216 causes non-syndromic retinitis pigmentosa and is associated with reduced TMEM216 expression.","authors":"Samantha Malka, Pooja Biswas, Anne-Marie Berry, Riccardo Sangermano, Mukhtar Ullah, Siying Lin, Matteo D'Antonio, Aleksandr Jestin, Xiaodong Jiao, Mathieu Quinodoz, Lori Sullivan, Jessica C Gardner, Emily M Place, Michel Michaelides, Karolina Kaminska, Omar A Mahroo, Elena Schiff, Genevieve Wright, Francesca Cancellieri, Veronika Vaclavik, Cristina Santos, Atta Ur Rehman, Sudeep Mehrotra, Hafiz Muhammad Azhar Baig, Muhammad Iqbal, Muhammad Ansar, Luisa Coutinho Santos, Ana Berta Sousa, Viet H Tran, Hiroko Matsui, Anjana Bhatia, Muhammad Asif Naeem, Shehla J Akram, Javed Akram, Sheikh Riazuddin, Carmen Ayuso, Eric A Pierce, Alison J Hardcastle, S Amer Riazuddin, Kelly A Frazer, J Fielding Hejtmancik, Carlo Rivolta, Kinga M Bujakowska, Gavin Arno, Andrew R Webster, Radha Ayyagari","doi":"10.1016/j.ajhg.2024.07.020","DOIUrl":"10.1016/j.ajhg.2024.07.020","url":null,"abstract":"<p><p>Genome analysis of individuals affected by retinitis pigmentosa (RP) identified two rare nucleotide substitutions at the same genomic location on chromosome 11 (g.61392563 [GRCh38]), 69 base pairs upstream of the start codon of the ciliopathy gene TMEM216 (c.-69G>A, c.-69G>T [GenBank: NM_001173991.3]), in individuals of South Asian and African ancestry, respectively. Genotypes included 71 homozygotes and 3 mixed heterozygotes in trans with a predicted loss-of-function allele. Haplotype analysis showed single-nucleotide variants (SNVs) common across families, suggesting ancestral alleles within the two distinct ethnic populations. Clinical phenotype analysis of 62 available individuals from 49 families indicated a similar clinical presentation with night blindness in the first decade and progressive peripheral field loss thereafter. No evident systemic ciliopathy features were noted. Functional characterization of these variants by luciferase reporter gene assay showed reduced promotor activity. Nanopore sequencing confirmed the lower transcription of the TMEM216 c.-69G>T allele in blood-derived RNA from a heterozygous carrier, and reduced expression was further recapitulated by qPCR, using both leukocytes-derived RNA of c.-69G>T homozygotes and total RNA from genome-edited hTERT-RPE1 cells carrying homozygous TMEM216 c.-69G>A. In conclusion, these variants explain a significant proportion of unsolved cases, specifically in individuals of African ancestry, suggesting that reduced TMEM216 expression might lead to abnormal ciliogenesis and photoreceptor degeneration.</p>","PeriodicalId":7659,"journal":{"name":"American journal of human genetics","volume":" ","pages":"2012-2030"},"PeriodicalIF":8.1,"publicationDate":"2024-09-05","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"https://www.ncbi.nlm.nih.gov/pmc/articles/PMC11393691/pdf/","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"142078890","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":1,"RegionCategory":"生物学","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"OA","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}
Pub Date : 2024-09-05Epub Date: 2024-08-02DOI: 10.1016/j.ajhg.2024.07.004
Aimee L Davidson, Kyriaki Michailidou, Michael T Parsons, Cristina Fortuno, Manjeet K Bolla, Qin Wang, Joe Dennis, Marc Naven, Mustapha Abubakar, Thomas U Ahearn, M Rosario Alonso, Irene L Andrulis, Antonis C Antoniou, Päivi Auvinen, Sabine Behrens, Marina A Bermisheva, Natalia V Bogdanova, Stig E Bojesen, Thomas Brüning, Helen J Byers, Nicola J Camp, Archie Campbell, Jose E Castelao, Melissa H Cessna, Jenny Chang-Claude, Stephen J Chanock, Georgia Chenevix-Trench, J Margriet Collée, Kamila Czene, Thilo Dörk, Mikael Eriksson, D Gareth Evans, Peter A Fasching, Jonine D Figueroa, Henrik Flyger, Manuela Gago-Dominguez, Montserrat García-Closas, Gord Glendon, Anna González-Neira, Felix Grassmann, Jacek Gronwald, Pascal Guénel, Andreas Hadjisavvas, Lothar Haeberle, Per Hall, Ute Hamann, Mikael Hartman, Peh Joo Ho, Maartje J Hooning, Reiner Hoppe, Anthony Howell, Anna Jakubowska, Elza K Khusnutdinova, Vessela N Kristensen, Jingmei Li, Joanna Lim, Annika Lindblom, Jenny Liu, Artitaya Lophatananon, Arto Mannermaa, Dimitrios A Mavroudis, Arjen R Mensenkamp, Roger L Milne, Kenneth R Muir, William G Newman, Nadia Obi, Mihalis I Panayiotidis, Sue K Park, Tjoung-Won Park-Simon, Paolo Peterlongo, Paolo Radice, Muhammad U Rashid, Valerie Rhenius, Emmanouil Saloustros, Elinor J Sawyer, Marjanka K Schmidt, Petra Seibold, Mitul Shah, Melissa C Southey, Soo Hwang Teo, Ian Tomlinson, Diana Torres, Thérèse Truong, Irma van de Beek, Annemieke H van der Hout, Camilla C Wendt, Alison M Dunning, Paul D P Pharoah, Peter Devilee, Douglas F Easton, Paul A James, Amanda B Spurdle
Co-observation of a gene variant with a pathogenic variant in another gene that explains the disease presentation has been designated as evidence against pathogenicity for commonly used variant classification guidelines. Multiple variant curation expert panels have specified, from consensus opinion, that this evidence type is not applicable for the classification of breast cancer predisposition gene variants. Statistical analysis of sequence data for 55,815 individuals diagnosed with breast cancer from the BRIDGES sequencing project was undertaken to formally assess the utility of co-observation data for germline variant classification. Our analysis included expected loss-of-function variants in 11 breast cancer predisposition genes and pathogenic missense variants in BRCA1, BRCA2, and TP53. We assessed whether co-observation of pathogenic variants in two different genes occurred more or less often than expected under the assumption of independence. Co-observation of pathogenic variants in each of BRCA1, BRCA2, and PALB2 with the remaining genes was less frequent than expected. This evidence for depletion remained after adjustment for age at diagnosis, study design (familial versus population-based), and country. Co-observation of a variant of uncertain significance in BRCA1, BRCA2, or PALB2 with a pathogenic variant in another breast cancer gene equated to supporting evidence against pathogenicity following criterion strength assignment based on the likelihood ratio and showed utility in reclassification of missense BRCA1 and BRCA2 variants identified in BRIDGES. Our approach has applicability for assessing the value of co-observation as a predictor of variant pathogenicity in other clinical contexts, including for gene-specific guidelines developed by ClinGen Variant Curation Expert Panels.
{"title":"Co-observation of germline pathogenic variants in breast cancer predisposition genes: Results from analysis of the BRIDGES sequencing dataset.","authors":"Aimee L Davidson, Kyriaki Michailidou, Michael T Parsons, Cristina Fortuno, Manjeet K Bolla, Qin Wang, Joe Dennis, Marc Naven, Mustapha Abubakar, Thomas U Ahearn, M Rosario Alonso, Irene L Andrulis, Antonis C Antoniou, Päivi Auvinen, Sabine Behrens, Marina A Bermisheva, Natalia V Bogdanova, Stig E Bojesen, Thomas Brüning, Helen J Byers, Nicola J Camp, Archie Campbell, Jose E Castelao, Melissa H Cessna, Jenny Chang-Claude, Stephen J Chanock, Georgia Chenevix-Trench, J Margriet Collée, Kamila Czene, Thilo Dörk, Mikael Eriksson, D Gareth Evans, Peter A Fasching, Jonine D Figueroa, Henrik Flyger, Manuela Gago-Dominguez, Montserrat García-Closas, Gord Glendon, Anna González-Neira, Felix Grassmann, Jacek Gronwald, Pascal Guénel, Andreas Hadjisavvas, Lothar Haeberle, Per Hall, Ute Hamann, Mikael Hartman, Peh Joo Ho, Maartje J Hooning, Reiner Hoppe, Anthony Howell, Anna Jakubowska, Elza K Khusnutdinova, Vessela N Kristensen, Jingmei Li, Joanna Lim, Annika Lindblom, Jenny Liu, Artitaya Lophatananon, Arto Mannermaa, Dimitrios A Mavroudis, Arjen R Mensenkamp, Roger L Milne, Kenneth R Muir, William G Newman, Nadia Obi, Mihalis I Panayiotidis, Sue K Park, Tjoung-Won Park-Simon, Paolo Peterlongo, Paolo Radice, Muhammad U Rashid, Valerie Rhenius, Emmanouil Saloustros, Elinor J Sawyer, Marjanka K Schmidt, Petra Seibold, Mitul Shah, Melissa C Southey, Soo Hwang Teo, Ian Tomlinson, Diana Torres, Thérèse Truong, Irma van de Beek, Annemieke H van der Hout, Camilla C Wendt, Alison M Dunning, Paul D P Pharoah, Peter Devilee, Douglas F Easton, Paul A James, Amanda B Spurdle","doi":"10.1016/j.ajhg.2024.07.004","DOIUrl":"10.1016/j.ajhg.2024.07.004","url":null,"abstract":"<p><p>Co-observation of a gene variant with a pathogenic variant in another gene that explains the disease presentation has been designated as evidence against pathogenicity for commonly used variant classification guidelines. Multiple variant curation expert panels have specified, from consensus opinion, that this evidence type is not applicable for the classification of breast cancer predisposition gene variants. Statistical analysis of sequence data for 55,815 individuals diagnosed with breast cancer from the BRIDGES sequencing project was undertaken to formally assess the utility of co-observation data for germline variant classification. Our analysis included expected loss-of-function variants in 11 breast cancer predisposition genes and pathogenic missense variants in BRCA1, BRCA2, and TP53. We assessed whether co-observation of pathogenic variants in two different genes occurred more or less often than expected under the assumption of independence. Co-observation of pathogenic variants in each of BRCA1, BRCA2, and PALB2 with the remaining genes was less frequent than expected. This evidence for depletion remained after adjustment for age at diagnosis, study design (familial versus population-based), and country. Co-observation of a variant of uncertain significance in BRCA1, BRCA2, or PALB2 with a pathogenic variant in another breast cancer gene equated to supporting evidence against pathogenicity following criterion strength assignment based on the likelihood ratio and showed utility in reclassification of missense BRCA1 and BRCA2 variants identified in BRIDGES. Our approach has applicability for assessing the value of co-observation as a predictor of variant pathogenicity in other clinical contexts, including for gene-specific guidelines developed by ClinGen Variant Curation Expert Panels.</p>","PeriodicalId":7659,"journal":{"name":"American journal of human genetics","volume":" ","pages":"2059-2069"},"PeriodicalIF":8.1,"publicationDate":"2024-09-05","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"https://www.ncbi.nlm.nih.gov/pmc/articles/PMC11393698/pdf/","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"141888202","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":1,"RegionCategory":"生物学","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"OA","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}
Pub Date : 2024-09-05Epub Date: 2024-08-05DOI: 10.1016/j.ajhg.2024.07.008
Marie Morimoto, Eunjin Ryu, Benjamin J Steger, Abhijit Dixit, Yoshihiko Saito, Juyeong Yoo, Amelie T van der Ven, Natalie Hauser, Peter J Steinbach, Kazumasa Oura, Alden Y Huang, Fanny Kortüm, Shinsuke Ninomiya, Elisabeth A Rosenthal, Hannah K Robinson, Katie Guegan, Jonas Denecke, Sankarasubramoney H Subramony, Callie J Diamonstein, Jie Ping, Mark Fenner, Elsa V Balton, Sam Strohbehn, Aimee Allworth, Michael J Bamshad, Mahi Gandhi, Katrina M Dipple, Elizabeth E Blue, Gail P Jarvik, C Christopher Lau, Ingrid A Holm, Monika Weisz-Hubshman, Benjamin D Solomon, Stanley F Nelson, Ichizo Nishino, David R Adams, Sukhyun Kang, William A Gahl, Camilo Toro, Kyungjae Myung, May Christine V Malicdan
The precise regulation of DNA replication is vital for cellular division and genomic integrity. Central to this process is the replication factor C (RFC) complex, encompassing five subunits, which loads proliferating cell nuclear antigen onto DNA to facilitate the recruitment of replication and repair proteins and enhance DNA polymerase processivity. While RFC1's role in cerebellar ataxia, neuropathy, and vestibular areflexia syndrome (CANVAS) is known, the contributions of RFC2-5 subunits on human Mendelian disorders is largely unexplored. Our research links bi-allelic variants in RFC4, encoding a core RFC complex subunit, to an undiagnosed disorder characterized by incoordination and muscle weakness, hearing impairment, and decreased body weight. We discovered across nine affected individuals rare, conserved, predicted pathogenic variants in RFC4, all likely to disrupt the C-terminal domain indispensable for RFC complex formation. Analysis of a previously determined cryo-EM structure of RFC bound to proliferating cell nuclear antigen suggested that the variants disrupt interactions within RFC4 and/or destabilize the RFC complex. Cellular studies using RFC4-deficient HeLa cells and primary fibroblasts demonstrated decreased RFC4 protein, compromised stability of the other RFC complex subunits, and perturbed RFC complex formation. Additionally, functional studies of the RFC4 variants affirmed diminished RFC complex formation, and cell cycle studies suggested perturbation of DNA replication and cell cycle progression. Our integrated approach of combining in silico, structural, cellular, and functional analyses establishes compelling evidence that bi-allelic loss-of-function RFC4 variants contribute to the pathogenesis of this multisystemic disorder. These insights broaden our understanding of the RFC complex and its role in human health and disease.
DNA 复制的精确调控对细胞分裂和基因组完整性至关重要。复制因子 C(RFC)复合物是这一过程的核心,它包括五个亚基,可将增殖细胞核抗原加载到 DNA 上,以促进复制和修复蛋白的招募,并提高 DNA 聚合酶的处理能力。虽然 RFC1 在小脑共济失调、神经病变和前庭反射综合征(CANVAS)中的作用已众所周知,但 RFC2-5 亚基对人类孟德尔疾病的贡献在很大程度上还未被探索。我们的研究将编码 RFC 复合物核心亚基的 RFC4 的双等位基因变异与一种未确诊的疾病联系起来,这种疾病的特征是不协调、肌肉无力、听力受损和体重下降。我们在九个受影响的个体中发现了 RFC4 中罕见的、保守的、预测的致病变异,所有这些变异都可能破坏 RFC 复合物形成所不可或缺的 C 端结构域。对先前确定的 RFC 与增殖细胞核抗原结合的冷冻电镜结构的分析表明,这些变体破坏了 RFC4 内部的相互作用和/或破坏了 RFC 复合物的稳定性。使用 RFC4 缺陷 HeLa 细胞和原代成纤维细胞进行的细胞研究表明,RFC4 蛋白减少,其他 RFC 复合物亚基的稳定性受到影响,RFC 复合物的形成受到干扰。此外,对 RFC4 变体的功能研究证实,RFC 复合物的形成受到了削弱,细胞周期研究表明,DNA 复制和细胞周期进展受到了干扰。我们将硅学、结构、细胞和功能分析相结合的综合方法提供了令人信服的证据,证明双等位基因功能缺失的RFC4变体有助于这种多系统疾病的发病机制。这些见解拓宽了我们对 RFC 复合物及其在人类健康和疾病中作用的认识。
{"title":"Expanding the genetic and phenotypic landscape of replication factor C complex-related disorders: RFC4 deficiency is linked to a multisystemic disorder.","authors":"Marie Morimoto, Eunjin Ryu, Benjamin J Steger, Abhijit Dixit, Yoshihiko Saito, Juyeong Yoo, Amelie T van der Ven, Natalie Hauser, Peter J Steinbach, Kazumasa Oura, Alden Y Huang, Fanny Kortüm, Shinsuke Ninomiya, Elisabeth A Rosenthal, Hannah K Robinson, Katie Guegan, Jonas Denecke, Sankarasubramoney H Subramony, Callie J Diamonstein, Jie Ping, Mark Fenner, Elsa V Balton, Sam Strohbehn, Aimee Allworth, Michael J Bamshad, Mahi Gandhi, Katrina M Dipple, Elizabeth E Blue, Gail P Jarvik, C Christopher Lau, Ingrid A Holm, Monika Weisz-Hubshman, Benjamin D Solomon, Stanley F Nelson, Ichizo Nishino, David R Adams, Sukhyun Kang, William A Gahl, Camilo Toro, Kyungjae Myung, May Christine V Malicdan","doi":"10.1016/j.ajhg.2024.07.008","DOIUrl":"10.1016/j.ajhg.2024.07.008","url":null,"abstract":"<p><p>The precise regulation of DNA replication is vital for cellular division and genomic integrity. Central to this process is the replication factor C (RFC) complex, encompassing five subunits, which loads proliferating cell nuclear antigen onto DNA to facilitate the recruitment of replication and repair proteins and enhance DNA polymerase processivity. While RFC1's role in cerebellar ataxia, neuropathy, and vestibular areflexia syndrome (CANVAS) is known, the contributions of RFC2-5 subunits on human Mendelian disorders is largely unexplored. Our research links bi-allelic variants in RFC4, encoding a core RFC complex subunit, to an undiagnosed disorder characterized by incoordination and muscle weakness, hearing impairment, and decreased body weight. We discovered across nine affected individuals rare, conserved, predicted pathogenic variants in RFC4, all likely to disrupt the C-terminal domain indispensable for RFC complex formation. Analysis of a previously determined cryo-EM structure of RFC bound to proliferating cell nuclear antigen suggested that the variants disrupt interactions within RFC4 and/or destabilize the RFC complex. Cellular studies using RFC4-deficient HeLa cells and primary fibroblasts demonstrated decreased RFC4 protein, compromised stability of the other RFC complex subunits, and perturbed RFC complex formation. Additionally, functional studies of the RFC4 variants affirmed diminished RFC complex formation, and cell cycle studies suggested perturbation of DNA replication and cell cycle progression. Our integrated approach of combining in silico, structural, cellular, and functional analyses establishes compelling evidence that bi-allelic loss-of-function RFC4 variants contribute to the pathogenesis of this multisystemic disorder. These insights broaden our understanding of the RFC complex and its role in human health and disease.</p>","PeriodicalId":7659,"journal":{"name":"American journal of human genetics","volume":" ","pages":"1970-1993"},"PeriodicalIF":8.1,"publicationDate":"2024-09-05","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"https://www.ncbi.nlm.nih.gov/pmc/articles/PMC11393705/pdf/","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"141896545","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":1,"RegionCategory":"生物学","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"OA","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}
Pub Date : 2024-09-05Epub Date: 2024-07-29DOI: 10.1016/j.ajhg.2024.07.003
Abdullah Abood, Larry D Mesner, Erin D Jeffery, Mayank Murali, Micah D Lehe, Jamie Saquing, Charles R Farber, Gloria M Sheynkman
A major fraction of loci identified by genome-wide association studies (GWASs) mediate alternative splicing, but mechanistic interpretation is hindered by the technical limitations of short-read RNA sequencing (RNA-seq), which cannot directly link splicing events to full-length protein isoforms. Long-read RNA-seq represents a powerful tool to characterize transcript isoforms, and recently, infer protein isoform existence. Here, we present an approach that integrates information from GWASs, splicing quantitative trait loci (sQTLs), and PacBio long-read RNA-seq in a disease-relevant model to infer the effects of sQTLs on the ultimate protein isoform products they encode. We demonstrate the utility of our approach using bone mineral density (BMD) GWAS data. We identified 1,863 sQTLs from the Genotype-Tissue Expression (GTEx) project in 732 protein-coding genes that colocalized with BMD associations (H4PP ≥ 0.75). We generated PacBio Iso-Seq data (N = ∼22 million full-length reads) on human osteoblasts, identifying 68,326 protein-coding isoforms, of which 17,375 (25%) were unannotated. By casting the sQTLs onto protein isoforms, we connected 809 sQTLs to 2,029 protein isoforms from 441 genes expressed in osteoblasts. Overall, we found that 74 sQTLs influenced isoforms likely impacted by nonsense-mediated decay and 190 that potentially resulted in the expression of unannotated protein isoforms. Finally, we functionally validated colocalizing sQTLs in TPM2, in which siRNA-mediated knockdown in osteoblasts showed two TPM2 isoforms with opposing effects on mineralization but exhibited no effect upon knockdown of the entire gene. Our approach should be to generalize across diverse clinical traits and to provide insights into protein isoform activities modulated by GWAS loci.
{"title":"Long-read proteogenomics to connect disease-associated sQTLs to the protein isoform effectors of disease.","authors":"Abdullah Abood, Larry D Mesner, Erin D Jeffery, Mayank Murali, Micah D Lehe, Jamie Saquing, Charles R Farber, Gloria M Sheynkman","doi":"10.1016/j.ajhg.2024.07.003","DOIUrl":"10.1016/j.ajhg.2024.07.003","url":null,"abstract":"<p><p>A major fraction of loci identified by genome-wide association studies (GWASs) mediate alternative splicing, but mechanistic interpretation is hindered by the technical limitations of short-read RNA sequencing (RNA-seq), which cannot directly link splicing events to full-length protein isoforms. Long-read RNA-seq represents a powerful tool to characterize transcript isoforms, and recently, infer protein isoform existence. Here, we present an approach that integrates information from GWASs, splicing quantitative trait loci (sQTLs), and PacBio long-read RNA-seq in a disease-relevant model to infer the effects of sQTLs on the ultimate protein isoform products they encode. We demonstrate the utility of our approach using bone mineral density (BMD) GWAS data. We identified 1,863 sQTLs from the Genotype-Tissue Expression (GTEx) project in 732 protein-coding genes that colocalized with BMD associations (H4PP ≥ 0.75). We generated PacBio Iso-Seq data (N = ∼22 million full-length reads) on human osteoblasts, identifying 68,326 protein-coding isoforms, of which 17,375 (25%) were unannotated. By casting the sQTLs onto protein isoforms, we connected 809 sQTLs to 2,029 protein isoforms from 441 genes expressed in osteoblasts. Overall, we found that 74 sQTLs influenced isoforms likely impacted by nonsense-mediated decay and 190 that potentially resulted in the expression of unannotated protein isoforms. Finally, we functionally validated colocalizing sQTLs in TPM2, in which siRNA-mediated knockdown in osteoblasts showed two TPM2 isoforms with opposing effects on mineralization but exhibited no effect upon knockdown of the entire gene. Our approach should be to generalize across diverse clinical traits and to provide insights into protein isoform activities modulated by GWAS loci.</p>","PeriodicalId":7659,"journal":{"name":"American journal of human genetics","volume":" ","pages":"1914-1931"},"PeriodicalIF":8.1,"publicationDate":"2024-09-05","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"https://www.ncbi.nlm.nih.gov/pmc/articles/PMC11393689/pdf/","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"141854508","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":1,"RegionCategory":"生物学","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"OA","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}
Pub Date : 2024-09-05Epub Date: 2024-07-29DOI: 10.1016/j.ajhg.2024.07.001
Tingyang Hu, Randy L Parrish, Qile Dai, Aron S Buchman, Shinya Tasaki, David A Bennett, Nicholas T Seyfried, Michael P Epstein, Jingjing Yang
Transcriptome-wide association study (TWAS) tools have been applied to conduct proteome-wide association studies (PWASs) by integrating proteomics data with genome-wide association study (GWAS) summary data. The genetic effects of PWAS-identified significant genes are potentially mediated through genetically regulated protein abundance, thus informing the underlying disease mechanisms better than GWAS loci. However, existing TWAS/PWAS tools are limited by considering only one statistical model. We propose an omnibus PWAS pipeline to account for multiple statistical models and demonstrate improved performance by simulation and application studies of Alzheimer disease (AD) dementia. We employ the Aggregated Cauchy Association Test to derive omnibus PWAS (PWAS-O) p values from PWAS p values obtained by three existing tools assuming complementary statistical models-TIGAR, PrediXcan, and FUSION. Our simulation studies demonstrated improved power, with well-calibrated type I error, for PWAS-O over all three individual tools. We applied PWAS-O to studying AD dementia with reference proteomic data profiled from dorsolateral prefrontal cortex of postmortem brains from individuals of European ancestry. We identified 43 risk genes, including 5 not identified by previous studies, which are interconnected through a protein-protein interaction network that includes the well-known AD risk genes TOMM40, APOC1, and APOC2. We also validated causal genetic effects mediated through the proteome for 27 (63%) PWAS-O risk genes, providing insights into the underlying biological mechanisms of AD dementia and highlighting promising targets for therapeutic development. PWAS-O can be easily applied to studying other complex diseases.
通过整合蛋白质组学数据和全基因组关联研究(GWAS)汇总数据,全转录组关联研究(TWAS)工具已被用于开展全蛋白质组关联研究(PWAS)。PWAS 确定的重要基因的遗传效应可能是通过基因调控的蛋白质丰度介导的,因此比 GWAS 基因位点更能说明潜在的疾病机制。然而,现有的 TWAS/PWAS 工具由于只考虑一种统计模型而受到限制。我们提出了一个考虑多种统计模型的综合 PWAS 管道,并通过对阿尔茨海默病(AD)痴呆症的模拟和应用研究证明了其性能的提高。我们采用聚合考奇关联检验(Aggregated Cauchy Association Test),从假设了互补统计模型的三个现有工具--TIGAR、PrediXcan 和 FUSION 所获得的 PWAS p 值推导出综合 PWAS (PWAS-O) p 值。我们的模拟研究表明,PWAS-O 比所有三个单独的工具都具有更高的功率,而且 I 型误差校准良好。我们将 PWAS-O 应用于研究 AD 痴呆症,其参考蛋白质组数据分析自欧洲血统个体死后大脑背外侧前额叶皮层。我们发现了 43 个风险基因,其中包括 5 个以前的研究未发现的基因,这些基因通过蛋白-蛋白相互作用网络相互连接,其中包括众所周知的 AD 风险基因 TOMM40、APOC1 和 APOC2。我们还验证了通过蛋白质组介导的 27 个(63%)PWAS-O 风险基因的因果遗传效应,从而深入了解了阿德痴呆症的潜在生物学机制,并突出了有希望的治疗开发靶点。PWAS-O很容易应用于其他复杂疾病的研究。
{"title":"Omnibus proteome-wide association study identifies 43 risk genes for Alzheimer disease dementia.","authors":"Tingyang Hu, Randy L Parrish, Qile Dai, Aron S Buchman, Shinya Tasaki, David A Bennett, Nicholas T Seyfried, Michael P Epstein, Jingjing Yang","doi":"10.1016/j.ajhg.2024.07.001","DOIUrl":"10.1016/j.ajhg.2024.07.001","url":null,"abstract":"<p><p>Transcriptome-wide association study (TWAS) tools have been applied to conduct proteome-wide association studies (PWASs) by integrating proteomics data with genome-wide association study (GWAS) summary data. The genetic effects of PWAS-identified significant genes are potentially mediated through genetically regulated protein abundance, thus informing the underlying disease mechanisms better than GWAS loci. However, existing TWAS/PWAS tools are limited by considering only one statistical model. We propose an omnibus PWAS pipeline to account for multiple statistical models and demonstrate improved performance by simulation and application studies of Alzheimer disease (AD) dementia. We employ the Aggregated Cauchy Association Test to derive omnibus PWAS (PWAS-O) p values from PWAS p values obtained by three existing tools assuming complementary statistical models-TIGAR, PrediXcan, and FUSION. Our simulation studies demonstrated improved power, with well-calibrated type I error, for PWAS-O over all three individual tools. We applied PWAS-O to studying AD dementia with reference proteomic data profiled from dorsolateral prefrontal cortex of postmortem brains from individuals of European ancestry. We identified 43 risk genes, including 5 not identified by previous studies, which are interconnected through a protein-protein interaction network that includes the well-known AD risk genes TOMM40, APOC1, and APOC2. We also validated causal genetic effects mediated through the proteome for 27 (63%) PWAS-O risk genes, providing insights into the underlying biological mechanisms of AD dementia and highlighting promising targets for therapeutic development. PWAS-O can be easily applied to studying other complex diseases.</p>","PeriodicalId":7659,"journal":{"name":"American journal of human genetics","volume":" ","pages":"1848-1863"},"PeriodicalIF":8.1,"publicationDate":"2024-09-05","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"https://www.ncbi.nlm.nih.gov/pmc/articles/PMC11393696/pdf/","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"141854530","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":1,"RegionCategory":"生物学","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"OA","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}
Pub Date : 2024-09-05DOI: 10.1016/j.ajhg.2024.08.003
Elyse Kozlowski, Geoffrey S Ginsburg, Bruce R Korf
{"title":"A new annual feature of AJHG: All of Us Research Program year in review.","authors":"Elyse Kozlowski, Geoffrey S Ginsburg, Bruce R Korf","doi":"10.1016/j.ajhg.2024.08.003","DOIUrl":"10.1016/j.ajhg.2024.08.003","url":null,"abstract":"","PeriodicalId":7659,"journal":{"name":"American journal of human genetics","volume":"111 9","pages":"1797"},"PeriodicalIF":8.1,"publicationDate":"2024-09-05","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"https://www.ncbi.nlm.nih.gov/pmc/articles/PMC11393664/pdf/","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"142144957","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":1,"RegionCategory":"生物学","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"OA","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}